Search

Search Constraints

You searched for: Author/Creator Voss, Tiffini

Search Results

3. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Issue 11 (13th October 2020)

4. FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD. (1st July 2019)

5. Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment. Issue 3 (16th January 2020)

6. O3‐10‐02: VERUBECESTAT‐INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID‐ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

7. P1‐038: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM EPOCH: A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE. (1st July 2006)

8. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS. (1st July 2019)

9. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS. (1st July 2019)

10. P2‐014: Relationship Between Volumetric MRI Parameters, APOE4 and MMSE Status at Baseline in The Verubecestat (MK‐8931) Mild to Moderate Alzheimer's Disease Phase 2/3 Trial. (1st July 2016)